TCBX vs KURA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
TCBX · Third Coast Bancshares$38.69 ▼ 1.05%
KURA · Kura Oncology$7.27 ▲ 6.91%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- TCBX +3.4%
- KURA -29.6%
Head to head
| Metric | TCBX | KURA |
|---|---|---|
| Price | $38.69 | $7.27 |
| Change today | ▼ 1.05% | ▲ 6.91% |
| Market cap | $646.36M | $646.74M |
| Return, 3 months | -12.6% | -26.2% |
| Return, year to date | +1.8% | -30.0% |
| Return, 1 year | +5.4% | -26.3% |
| P/E (TTM) | 9.9 | – |
| P/B | 1.0 | 13.4 |
| P/E percentile vs own 5y | 23rd | 88th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +19.1% | +36.5% |
| Net profit growth (YoY) | +5.2% | -3.3% |
| Gross margin | – | 99.3% |
| Operating margin | – | -411.9% |
| Net margin | 28.7% | -384.3% |
| Return on equity | 11.9% | -167.7% |
| Analyst target vs. price | +27.5% | +278.3% |
| Analyst buy share | 33% | 100% |
| RSI (14) | 34 | 29 |
| 30-day volatility | 23.4% | 96.0% |
| Max drawdown, 1 year | -16.1% | -50.0% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- KURA is the largest of the group by market value.
- TCBX has returned the most over the past year.
- KURA is growing revenue fastest.
- TCBX keeps the most profit per dollar of sales.
- TCBX has been the calmest stock over the last 30 days.